June 5, 2020

The Niche

Knoepfler lab stem cell blog

OPC1

3 min read

As I posted recently, Asterias Biotherapeutics has had good early safety results so far in its historic stem cell trial for spinal cord injury and now the company presented some early, encouraging hints at efficacy.  However, a caveat here is that this is not an RCT (randomized controlled trial). Ed Wirth, CMO of Asterias, presented the early data at the 55th Annual Scientific Meeting of the International Spinal Cord Society. You can take a look at the very interesting talk slides here. Asterias is a subsidiary …Read More

1 min read

A lot has happened in 2014 in the stem cell and regenerative medicine field and so much of it has been good news. These positive developments are often the result of many years of creative, hard work by amazing teams of researchers. Here is my top 10 list of these exciting advances. 1. First IPSC study in humans by team led by Masayo Takahashi. 2. and 3. Major Diabetes advances: ViaCyte starts stem cell-based clinical trial for Diabetes and multiple teams of researchers make human …Read More

3 min read

The BioTime subsidiary, Asterias, has received FDA approval for a combined Phase I/IIa clinical trial of OPC1 for treating spinal cord injury. BioTime (BTX) and Asterias (ASTY) have picked up the portfolio of the former Geron clinical trial using oligodendrocyte precursor cells (OPC). Asterias also acquired a second element from Geron in the form of a lung cancer treatment based on stem cells that sounds quite intriguing. To learn more about this exciting news I interviewed Jane Lebkowski, President of Research and Development at Asterias. 1. …Read More